Ad hoc announcement pursuant to Art. 53 LR
Proceeds expected to fund global ENIGMA-TRS studies and extend cash runway beyond pivotal 12-week results, supporting development of
Publication presents clinical findings highlighting evenamide’s glutamatergic modulation as a therapeutic strategy for patients with inadequate response or treatment-resistant
Milan, Italy, and Morristown, NJ, USA, January 7, 2026 – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development
Ad hoc announcement pursuant to Art. 53 LR
EP4615820 – “Crystalline Forms of Evenamide” is expected to extend asset exclusivity in EU into 2044
Evenamide is currently being
Morristown, NJ, USA, and Milan, Italy, December 22, 2025, 07:00 am ET – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on
Ad hoc announcement pursuant to Art. 53 LR
ENIGMA-TRS 2 is a global, randomized, double-blind, placebo-controlled 12-week Phase III clinical study designed to enroll at least 400
New post-hoc analyses highlighting the clinical benefit of evenamide for patients with treatment-resistant schizophrenia (TRS) or those inadequately responding to their
Ad hoc announcement pursuant to Art. 53 LR
Milan, Italy, September 16, 2025, 07:00 am CEST – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a
The importance of glutamate release modulation by evenamide used as an add-on therapy for patients with schizophrenia inadequately responding to their second-
Ad hoc announcement pursuant to Art. 53 LR
ENIGMA-TRS 1 is an international, one-year, double-blind, placebo-controlled Phase III study in at least 600 patients; 12-week study
The information on the following pages may be made available in the United States. By clicking on the link below, you agree that you are in the United States.
